Leerink Swann Analysts Give Jazz Pharmaceuticals plc – (JAZZ) a $170.00 Price Target

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) received a $170.00 price objective from equities research analysts at Leerink Swann in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Leerink Swann’s target price would indicate a potential upside of 10.23% from the company’s previous close.

Several other analysts have also recently issued reports on JAZZ. Cantor Fitzgerald started coverage on Jazz Pharmaceuticals plc – in a research report on Friday, December 16th. They set an “overweight” rating and a $187.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating and set a $192.00 target price on shares of Jazz Pharmaceuticals plc – in a research report on Thursday, January 12th. Barclays PLC reiterated an “overweight” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals plc – in a research report on Wednesday, January 18th. Mizuho restated a “neutral” rating and set a $127.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, January 18th. Finally, Goldman Sachs Group Inc restated a “buy” rating and set a $170.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, January 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals plc – has an average rating of “Buy” and an average price target of $181.23.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 1.35% during trading on Thursday, reaching $152.14. 321,964 shares of the company were exchanged. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $160.00. The firm’s 50 day moving average price is $143.48 and its 200 day moving average price is $123.54. The company has a market capitalization of $9.09 billion, a PE ratio of 23.73 and a beta of 1.22.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a return on equity of 30.50% and a net margin of 24.81%. The business had revenue of $396.62 million for the quarter, compared to analysts’ expectations of $398.91 million. During the same quarter in the prior year, the business posted $2.60 EPS. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals plc – will post $11.10 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Analysts Give Jazz Pharmaceuticals plc – (JAZZ) a $170.00 Price Target” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/04/21/jazz-pharmaceuticals-plc-jazz-given-a-170-00-price-target-at-leerink-swann-updated.html.

In other news, SVP Karen J. Wilson sold 11,458 shares of Jazz Pharmaceuticals plc – stock in a transaction on Monday, April 10th. The stock was sold at an average price of $152.24, for a total value of $1,744,365.92. Following the transaction, the senior vice president now directly owns 27,158 shares in the company, valued at approximately $4,134,533.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals plc – stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $134.55, for a total value of $26,910.00. Following the completion of the transaction, the senior vice president now owns 16,486 shares in the company, valued at $2,218,191.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,942 shares of company stock valued at $2,098,147. 3.90% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Howard Hughes Medical Institute bought a new position in shares of Jazz Pharmaceuticals plc – during the third quarter worth about $112,000. Brave Asset Management Inc increased its position in shares of Jazz Pharmaceuticals plc – by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 810 shares in the last quarter. Bridges Investment Management Inc. bought a new position in shares of Jazz Pharmaceuticals plc – during the first quarter worth about $208,000. Daiwa Securities Group Inc. increased its position in shares of Jazz Pharmaceuticals plc – by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 150 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals plc – by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 37 shares in the last quarter. Institutional investors and hedge funds own 88.56% of the company’s stock.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply